title: Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
abstract: To describe the effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen in naive HIV-1-infected patients, as there is a lack of data with this combination.
  
  
  
  This was an observational, retrospective, multicentre study in eight Spanish hospitals. All antiretroviral-naive patients ≥18 years old and starting abacavir/lamivudine + rilpivirine were included. Effectiveness (ITT and on-treatment) and safety (adverse events and laboratory parameters) were assessed during follow-up. Values are expressed as n (%) or median (IQR). The Wilcoxon signed-rank test was used to compare baseline and 6 and 12 month values.
  
  
  
  Eighty-four patients were included [93% males, age = 36 (30-45) years]. Time since HIV diagnosis was 12 (4-35) months. Fifty-one per cent of patients had comorbidities. Baseline CD4+ was 425 (340-519) cells/mm3and baseline HIV-RNA was 19 000 (9500-42 000) copies/mL. Median follow-up was 18 (9-22) months; 100% and 68% patients with at least 6 and 12 months, respectively. At 6 and 12 months effectiveness was 94% and 86% by ITT analysis and 96% and 97% by on-treatment analysis. At 12 months, there were significant increases in CD4+ (+262 cell/mm3) and HDL cholesterol (+4 mg/dL) and a significant decrease in the total cholesterol/HDL cholesterol ratio (-0.2). There were two (2.4%) virological failures (HIV-RNA 50-100 copies/mL); one patient later achieving virological suppression without changing the treatment. Six patients (7.1%) changed treatment due to reasons other than virological failure or side effects. One patient discontinued treatment due to gastrointestinal complaints attributed to abacavir/lamivudine.
  
  
  
  Abacavir/lamivudine + rilpivirine was an effective and safe option in a selected group of HIV-1-infected treatment-naive patients.
authors: Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain acurran@vhebron.net.
authors: Adrian
authors: A
authors: Curran
authors: Hospital Clinic-IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
authors: Jhon
authors: J
authors: Rojas
authors: Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
authors: Alfonso
authors: A
authors: Cabello
authors: Hospital Universitario Infanta Leonor, Madrid, Spain.
authors: Jesús
authors: J
authors: Troya
authors: Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet, Spain.
authors: Arkaitz
authors: A
authors: Imaz
authors: Hospital Arnau de Vilanova, Lleida, Spain.
authors: Pere
authors: P
authors: Domingo
authors: Hospital Clinic-IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
authors: Esteban
authors: E
authors: Martinez
authors: Hospital Universitario Infanta Leonor, Madrid, Spain.
authors: Pablo
authors: P
authors: Ryan
authors: Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
authors: Miguel
authors: M
authors: Górgolas
authors: Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet, Spain.
authors: Daniel
authors: D
authors: Podzamczer
authors: Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors: Hernando
authors: H
authors: Knobel
authors: Hospital General de Elche, Universidad Miguel Hernández, Alicante, Spain.
authors: Félix
authors: F
authors: Gutiérrez
authors: Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors: Esteban
authors: E
authors: Ribera
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000008:administration & dosage* / Q000009:adverse effects*; D004338:Drug Combinations; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006761:Hospitals; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000068696:Rilpivirine / Q000008:administration & dosage* / Q000009:adverse effects*; D013030:Spain; D016896:Treatment Outcome; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D000068696:Rilpivirine; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir